Lancellotta, V. (Valentina)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
3 results
Search Results
Now showing 1 - 3 of 3
- Review paper Personalized re-treatment strategy for uveal melanoma local recurrences after interventional radiotherapy (brachytherapy): single institution experience and systematic literature review(Termedia Sp. z.o.o., 2019) Martinez-Monge, R. (Rafael); Kovács, G. (Gyorgy); Sammarco, M.G. (M. G.); Azario, L. (L.); Caputo, C.G. (C. G.); Scupola, A. (A.); Gambacorta, M.A. (M. A.); Autorino, R. (R.); Valentini, V. (Vincenzo); Tagliaferri, L. (Luca); Blasi, M.A. (Maria Antonietta); Lancellotta, V. (Valentina); Fionda, B. (Bruno); Pagliara, M.M. (M. M.); Cammelli, S. (S.)Purpose: To report the results of a patient’s tailored therapeutic approach using a second course of interventional radiotherapy (brachytherapy) in patients with locally recurrent uveal melanoma. Material and methods: Patients who had already undergone ocular brachytherapy treated at our IOC (Interventional Oncology Center) were considered. Five patients who has received a second course of treatment with a plaque after local recurrences were included in our study. Re-irradiation was performed with Ruthenium-106 (prescribed dose to the apex 100 Gy) or with Iodine-125 plaques (prescribed dose to the apex 85 Gy). Moreover, a systematic literature search was conducted through three electronic databases, including Medline/PubMed, Scopus, and Embase. Results: All patients were initially treated with Ruthenium-106 plaque; the re-irradiation was performed with Ruthenium-106 plaque in three cases and with Iodine in two cases. Mean time between the first and the second plaque was 56.8 months (range, 25-93 months). Local tumor control rate was 100%, no patient underwent secondary enucleation owing to re-treatment failure. Distant metastasis occurred in 1 patient after 6 months from re-treatment. After a median follow-up of 44.2 months (range, 26-65 months) from re-treatment, all patients experienced worsening of the visual acuity (median visual acuity was 0.42 at time of recurrence and decline to 0.24 at the most recent follow-up); cataract occurred in two cases, no patient developed scleral necrosis. We considered 2 papers for a systematic review. Conclusions: In selected cases, especially in presence of marginal local recurrence, a personalized re-treatment strategy with a plaque may offer high probability of tumor control and organ preservation but worsening of visual acuity.
- ENT COBRA ONTOLOGY: the covariates classification system proposed by the Head & Neck and Skin GEC-ESTRO working group for interdisciplinary standardized data collection in head and neck patient cohorts treated with interventional radiotherapy (brachytherapy)(Termedia Publishing, 2018) Dinapoli, N. (Nicola); Boldrini, L. (Luca); Bussu, F. (Francesco); Martinez-Monge, R. (Rafael); Kovács, G. (Gyorgy); Takácsi-Nagy, Z. (Zoltán); Gatta, R. (Roberto); Lanzotti, V. (Vito); Rovirosa, A. (Angeles); Budrukkar, A. (Ashwini); Guinot, J.L. (Jose Luis); Damiani, A. (Andrea); Soror, T. (Tamer); Valentini, V. (Vincenzo); Tagliaferri, L. (Luca); Lancellotta, V. (Valentina); Cambeiro, M. (Mauricio); Niehoff, P. (Peter); Fionda, B. (Bruno); Hildebrandt, G. (Guido); Johansson, B. (Bengt); Lenkowicz, J. (Jacopo); Meyer, J.E. (Jens E.)Purpose: Clinical data collecting is expensive in terms of time and human resources. Data can be collected in different ways; therefore, performing multicentric research based on previously stored data is often difficult. The primary objective of the ENT COBRA (COnsortium for BRachytherapy data Analysis) ontology is to define a specific terminological system to standardized data collection for head and neck (H&N) cancer patients treated with interventional radiotherapy. Material and methods: ENT-COBRA is a consortium for standardized data collection for H&N patients treated with interventional radiotherapy. It is linked to H&N and Skin GEC-ESTRO Working Group and includes 11 centers from 6 countries. Its ontology was firstly defined by a multicentric working group, then evaluated by the consortium followed by a multi-professional technical commission involving a mathematician, an engineer, a physician with experience in data storage, a programmer, and a software expert. Results: Two hundred and forty variables were defined on 13 input forms. There are 3 levels, each offering a specific type of analysis: 1. Registry level (epidemiology analysis); 2. Procedures level (standard oncology analysis); 3. Research level radiomics analysis). The ontology was approved by the consortium and technical commission; an ad-hoc software architecture (“broker”) remaps the data present in already existing storage systems of the various centers according to the shared terminology system. The first data sharing was successfully performed using COBRA software and the ENT COBRA Ontology, automatically collecting data directly from 3 different hospital databases (Lübeck, Navarra, and Rome) in November 2017. Conclusions: The COBRA Ontology is a good response to the multi-dimensional criticalities of data collection, retrieval, and usability. It allows to create a software for large multicentric databases with implementation of specific remapping functions wherever necessary. This approach is well-received by all involved parties, primarily because it does not change a single center’s storing technologies, procedures, and habits.
- PO-1045 Retreatment using Ru-106 or I-125 plaque in uveal melanoma locally recurrent after brachytherapy(Elsevier BV, 2019) Martinez-Monge, R. (Rafael); Kovács, G. (Gyorgy); Sammarco, M.G. (M. G.); Azario, L. (L.); Caputo, C.G. (C. G.); Scupola, A. (A.); Blasius, B. (B.); Gambacorta, M.A. (M. A.); Autorino, R. (R.); Valentini, V. (Vincenzo); Tagliaferri, L. (Luca); Lancellotta, V. (Valentina); Fionda, B. (Bruno); Pagliara, M.M. (M. M.); Cammelli, S. (S.)Purpose or Objective:To present the results of a patient therapeutic approach using a second course of Interventional Radiotherapy (Brachytherapy) in a setting of patients with local recurrence of uveal melanoma. Material and Methods: Patients who had already undergone ocular brachytherapy at IOC (Interventional Oncology Center) of the “Gemelli ART” (Advanced Radiation Therapy) of Rome were considered. In this group, five patients with a local recurrence that received a second course of treatment with a plaque were included in our analysis. The reirradiation was performed with a plaque of Ruthenium-106 (dose prescribed to the apex 100 Gy) or of Iodine-125 (dose prescribed to the apex 85Gy).